Navigation Links
Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
Date:10/29/2009

NANJING, China, Oct. 29 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire a 74.49% stake in ChinaVax, a Cayman Islands company that, as its sole business, holds a 13.27% stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen"). After the completion of this acquisition, and together with a 37.5% stake in Jiangsu Yanshen acquired in May 2009, Simcere will control a 50.77% stake in Jiangsu Yanshen.

"China's emerging vaccine industry has shown strong growth potential. We are delighted to make this additional investment in Jiangsu Yanshen, following our acquisition of a 37.5% stake earlier this year," commented Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group. "This investment is in line with Simcere's mid-to-long-term strategy and demonstrates Simcere's continuing progress in China's vaccine industry."

Located in Changzhou, Jiangsu Province, Jiangsu Yanshen is a leading China-based developer and manufacturer of vaccines. Jiangsu Yanshen was awarded a new drug certificate and production license from China's State Food and Drug Administration (SFDA) on September 18, 2009 for its Influenza A (H1N1) vaccine. Jiangsu Yanshen has subsequently received orders from China's Ministry of Industry and Information Technology for 6.3 million doses of the Influenza A (H1N1) vaccine.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange A
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Top-Line Data Expected in the Third Quarter --, ... VIAP ), a biotechnology company focused on the development ... that,it has completed the last patient visit in its ... be analyzed to determine,VIA-2291,s effect on inflammation, and the ...
... Modigene,s CTP Technology for Extending ... of Action of Therapeutic Proteins -, NES-ZIONA, Israel, ... noted the successful completion of a Phase,III clinical trial ... uses the naturally occurring CTP,peptide to extend the duration ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Modigene Platform Validated in Independent Phase III Trial of CTP Technology 2Modigene Platform Validated in Independent Phase III Trial of CTP Technology 3
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... Calif., June 24 Novasys Medical, Inc., a developer ... as of July 1, 2009, First Coast Service Options, ... over 3 million beneficiaries in Florida, Puerto Rico and ... treatment for women with stress urinary incontinence (SUI) from ...
... Plans (MHP) is pleased to offer Mercy One ... www.mercyhealthplans.com . This online quoting and sales ... and brokers with Mercy One (TM), health insurance for ... Connect(TM) utilizes a customer-friendly online ecommerce platform that ...
... Purchase Agreement will expedite the purchasing process for groups ... IRVINE, Calif., June 24 ChromaDex Corp., (OTC Bulletin ... contract research, announced today that the National Institutes of ... Company. The Agreement covers all products and services ...
... , , , , Chocolate and ... June 24 Experimenting with flavors, flexibility and variety, ... with chocolate and candy innovation that will drive consumer purchasing ... Association,s (NCA) Confectionery Industry Trend Report 2009. Even in economic ...
... CNI ... Technician Executive Division of the California Society of Health System Pharmacists. , ... Orange, CA (PRWEB) June 24, 2009 -- CNI ... for the Technician Executive Division of the California Society of Health System Pharmacists. As ...
... Vet-A-Mix announces ... at-risk horses. , ... (PRWEB) June 24, 2009 -- Equine obesity is on the rise in the United States. ... higher risk for laminitis: a debilitating condition responsible for thousands of deaths each year. According ...
Cached Medicine News:Health News:First Coast Medicare to Provide Case by Case Reimbursement for the Renessa(R) Treatment for Incontinence in Women 2Health News:First Coast Medicare to Provide Case by Case Reimbursement for the Renessa(R) Treatment for Incontinence in Women 3Health News:Mercy Health Plans Launches MercyOne Connect(TM) 2Health News:ChromaDex Establishes a Blanket Purchase Agreement With the National Institutes of Health 2Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 2Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 3Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 4Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 5Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 6Health News:CNI Pharmacy Technician Program 2Health News:Equine Obesity is Associated with Significant Health Issues, Including Insulin Resistance and Laminitis 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
This unit is the finest standalone handswitch bipolar unit available....
...
...
Medicine Products: